Stockscreener 앱 받기
15.67
2.61%
-0.42
시장 영업 전:
15.21
-0.46
-2.94%
전일 마감가:
$16.09
열려 있는:
$16.11
하루 거래량:
1.07M
Relative Volume:
1.25
시가총액:
$1.16B
수익:
$288.00K
순이익/손실:
$-228.06M
주가수익비율:
-3.6871
EPS:
-4.25
순현금흐름:
$-168.82M
1주 성능:
+10.04%
1개월 성능:
+19.44%
6개월 성능:
-12.90%
1년 성능:
+23.78%
1일 변동 폭
$15.40
$16.16
1주일 범위
$14.36
$16.29
52주 변동 폭
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
명칭
Viridian Therapeutics Inc
전화
617.272.4600
주소
221 CRESCENT STREET, WALTHAM
VRDN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
15.67 | 1.16B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.06 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.84 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
304.67 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
586.76 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
276.53 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 개시 | TD Cowen | Buy |
| 2024-09-11 | 재확인 | Needham | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-05-09 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 개시 | BTIG Research | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-05-30 | 개시 | RBC Capital Mkts | Outperform |
| 2023-04-17 | 개시 | Wells Fargo | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2022-12-19 | 개시 | Cowen | Outperform |
| 2022-12-19 | 개시 | Needham | Buy |
| 2022-12-16 | 개시 | Credit Suisse | Outperform |
| 2022-12-01 | 개시 | H.C. Wainwright | Buy |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2021-11-18 | 개시 | SVB Leerink | Outperform |
| 2021-10-12 | 개시 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by California State Teachers Retirement System - Defense World
Viridian Therapeutics: The Song Remains The Same (NASDAQ:VRDN) - Seeking Alpha
Transcript : Viridian Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.22 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Where are the Opportunities in (VRDN) - news.stocktradersdaily.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats By Investing.com - Investing.com Nigeria
Ameriprise Financial Inc. Increases Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics to Participate in Upcoming June 2025 Investor Conferences - BioSpace
Viridian Therapeutics to Participate in Upcoming June Investor C - GuruFocus
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - Business Wire
Bank of America Corp DE Grows Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 13,990 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Increased by Nuveen Asset Management LLC - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Millennium Management LLC - Defense World
Needham & Company LLC Reiterates “Buy” Rating for Viridian Therapeutics (NASDAQ:VRDN) - Defense World
Viridian Therapeutics’ veligrotug shows durability in Phase III TED trial - Yahoo Finance
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $36.70 Average Target Price from Analysts - Defense World
Veligrotug Shows Durability for Thyroid Eye Disease in Phase 3 Trial Results - HCPLive
Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalysts - Investing.com Nigeria
Viridian Therapeutics (VRDN) Maintains Stable Outlook with Buy Rating | VRDN Stock News - GuruFocus
Viridian Therapeutics: Buy Rating Affirmed on Promising Phase III Results and Strategic Growth Plans - TipRanks
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - BioSpace
Viridian Therapeutics Announces Positive Long-Term Durability Da - GuruFocus
Viridian's (VRDN) Veligrotug Shows Promising Long-Term Results in TED Treatment | VRDN Stock News - GuruFocus
Viridian Announces Positive Long-Term Data From Phase 3 Trial Of Veligrotug In Thyroid Eye Disease - Nasdaq
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) | VRDN Stock News - GuruFocus
Northern Trust Corp Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Dimensional Fund Advisors LP Sells 271,156 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Viridian Therapeutics (VRDN) to Release Quarterly Earnings on Wednesday - Defense World
Q2 EPS Estimate for Viridian Therapeutics Lowered by Analyst - Defense World
Wedbush Boosts Earnings Estimates for Viridian Therapeutics - Defense World
Q2 EPS Estimate for Viridian Therapeutics Reduced by Analyst - Defense World
B. Riley Boosts Earnings Estimates for Viridian Therapeutics - Defense World
Needham & Company LLC Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - The AM Reporter
JMP Securities Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $38.00 - Defense World
Royal Bank of Canada Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $45.00 - Defense World
Q1 Earnings Estimate for VRDN Issued By HC Wainwright - Defense World
The Goldman Sachs Group Issues Pessimistic Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - Defense World
Needham & Company LLC Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - Defense World
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - BioSpace
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus
What 5 Analyst Ratings Have To Say About Viridian Therapeutics - Benzinga
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates - MSN
FDA Grants Breakthrough Therapy Status to Viridian's (VRDN) Veligrotug | VRDN Stock News - GuruFocus
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Target Price Adjusted by RBC Capita - GuruFocus
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Ratin - GuruFocus
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Rating | VRDN Stock News - GuruFocus
Viridian Therapeutics Inc (VRDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
2.03%
자본화:
|
볼륨(24시간):